Compare CNNE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | ASMB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.0M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | CNNE | ASMB |
|---|---|---|
| Price | $14.80 | $26.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $20.25 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 446.6K | 245.6K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $16.90 |
| 52 Week High | $21.92 | $39.71 |
| Indicator | CNNE | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 49.77 |
| Support Level | $13.97 | $26.18 |
| Resistance Level | $14.99 | $30.68 |
| Average True Range (ATR) | 0.42 | 1.50 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 52.46 | 31.53 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.